Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6011.5000 -59.50 (-0.98%)
NSE Jan 23, 2026 15:48 PM
Volume: 460.5K
 

6011.50
-0.98%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 21.2% YoY to | 995.3 crore (I-direct estimate: | 1151.2 crore) mainly due to lower base of import alert in Q1FY18, currency tailwinds and strong growth in the carotenoid segment EBITDA margins improved 554 bps to 35.4% (I-direct estimate: 36%) mainly due to strong gross margins, lower other expenditure. EBITDA grew 43.7% YoY to | 351.9 crore (I-direct estimate: | 414.4 crore) Net profit grew 50.8% to | 266.2 crore (I-direct estimate: | 308.1...
Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr
More from Divi's Laboratories Ltd.
Recommended